79.06
price down icon0.29%   -0.23
after-market Handel nachbörslich: 78.88 -0.18 -0.23%
loading

Merck Co Inc Aktie (MRK) Neueste Nachrichten

pulisher
Jun 18, 2025

Why the Market Dipped But Merck (MRK) Gained Today - Yahoo

Jun 18, 2025
pulisher
Jun 18, 2025

Merck (MRK) Gains as CDC Agenda Omits Gardasil Dose Changes - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Merck stock up as CDC meeting excludes HPV shots (MRK:NYSE) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Merck (MRK) Expands Deals with Chinese Pharma Companies - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Kennedy's new US vaccine panel to discuss measles shot for children - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Merck Stock Analysis: Is Today’s Massive 2% Spike a Breakout? - Daily Chhattisgarh News

Jun 18, 2025
pulisher
Jun 18, 2025

Merck: Phase 3 trial in prostate cancer - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Merck Doses First Patient in Phase 3 Trial of Prostate Cancer Drug Candidate - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Merck (MRK) Begins Phase 3 Trial for New Prostate Cancer Treatment | MRK Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough Prostate Cancer Drug Enters Phase 3 Trial: New Hope for 31% Survival Rate Disease - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

2 Dividend Stocks to Buy and Never Sell - The Motley Fool

Jun 18, 2025
pulisher
Jun 18, 2025

Dividend Growth Remains a Key Priority for Merck - Insider Monkey

Jun 18, 2025
pulisher
Jun 17, 2025

Merck (MRK) Dips More Than Broader Market: What You Should Know - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC

Jun 17, 2025
pulisher
Jun 16, 2025

Supreme Court Decision Lets Fosamax Lawsuit Against Merck (MRK) Proceed - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Merck bid to stop Fosamax suit thwarted by Supreme Court - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy? - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Merck Manuals Launches AI-powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources - PR Newswire

Jun 16, 2025
pulisher
Jun 15, 2025

Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

Merck’s SWOT analysis: stock faces keytruda LOE challenge amid pipeline promise - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Merck (MRK) Secures Landmark FDA Approval for Keytruda in Head and Neck Cancer - Daily Chhattisgarh News

Jun 14, 2025
pulisher
Jun 14, 2025

Immuno-Oncology and Precision Medicine Trends Led by Merck & Pfizer Boost Gastric Cancer Market Growth - openPR.com

Jun 14, 2025
pulisher
Jun 14, 2025

SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit - AOL.com

Jun 13, 2025
pulisher
Jun 13, 2025

Merck (MRK) Boosted by Rising MMR Vaccine Demand Amid Measles Outbreaks - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda - Investopedia

Jun 13, 2025
pulisher
Jun 13, 2025

FDA Approves Merck's Keytruda for Head and Neck Cancer - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Merck's Keytruda gains additional indications in head and neck cancer - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Merck: FDA approves Keytruda for head and neck cancer - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA Approves Merck's Anti-PD-1 Therapy - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA Approves Merck's Keytruda for Specific Head and Neck Cancer | MRK Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Merck (MRK) Awaits EU Approval for New Pet Medicine - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Merck Animal Health Gets EU Positive Opinion for Numelvi Tablets for Dogs - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck (MRK) Awaits EU Approval for Innovative Canine Drug | MRK Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

RFK Jr.’s New Vaccine Panel Includes Two Paid Witnesses Against Merck - Bloomberg.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck Animal Health gets EU backing for Numelvi tablets (MRK:NYSE) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Merck’s canine dermatitis drug Numelvi gets positive EU opinion - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs - StreetInsider

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: EU Panel Backs Merck's Novel Dog Itch Treatment That Works From Day One - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Kalkine : Is Merck Set for Strong Payouts This Dividend Season Dow Jones Industrial Average - Kalkine Media

Jun 12, 2025
pulisher
Jun 12, 2025

Exclusive-Kennedy’s new vaccine adviser was expert witness against Merck vaccine - The Mighty 790 KFGO

Jun 12, 2025
pulisher
Jun 12, 2025

Controversy Surrounds Merck (MRK) Due to Vaccine Litigation Ties - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

RFK Jr’s vaccine advisor has worked against Merck shot (MRK) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck (MRK) Initiates Late-Stage Dengue Vaccine Trial - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Merck: Phase 3 trial for dengue vaccine - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck begins late-stage trial for single dose dengue vaccine - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Merck (MRK) Launches Key Phase 3 Trial for Dengue Vaccine | MRK Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Merck begins phase 3 trial of single-dose dengue vaccine - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

Merck begins phase 3 trial of single-dose dengue vaccine By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Merck initiates phase 3 study for dengue vaccine in children By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Merck initiates phase 3 study for dengue vaccine in children - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate | MRK Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

MRK Stock Quote Price and Forecast - CNN

Jun 12, 2025
pulisher
Jun 12, 2025

Merck's Game-Changing Single-Dose Dengue Vaccine Enters Final Testing PhaseWhat Sets It Apart - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Here's Why Merck (MRK) Fell More Than Broader Market - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

Merck (MRK) Stock Declines 1.44%, Continuing Year-Long Downtrend - Daily Chhattisgarh News

Jun 11, 2025
pulisher
Jun 11, 2025

Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

Unpacking the Latest Options Trading Trends in Merck & Co - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty - BioWorld MedTech

Jun 11, 2025
drug_manufacturers_general NVS
$115.77
price down icon 0.16%
$289.33
price down icon 0.10%
drug_manufacturers_general PFE
$23.97
price up icon 0.38%
$108.50
price up icon 0.46%
drug_manufacturers_general SNY
$47.86
price up icon 0.50%
Kapitalisierung:     |  Volumen (24h):